DAIICHI SANKYO, INC

Daiichi Sankyo, Inc. specializes in the manufacturing and supply of specialized pharmaceutical preparations, with a focused expertise in oncology therapeutics, particularly oral small-molecule drugs. The company delivers clinically validated active pharmaceutical ingredients and finished dosage forms, including capsule formulations such as pexidartinib (TURALIO), demonstrating deep competency in GMP-compliant production, drug substance handling, and controlled-release oral solid dosage systems. Their technical capabilities encompass end-to-end pharmaceutical manufacturing, from bulk API processing to finished product packaging, with strict adherence to FDA and VA pharmacovigilance standards. A key differentiator is their ability to sustain long-term supply chains for niche oncology agents requiring precise dosing, cold-chain logistics, and specialized stability testing. The contractor maintains a consistent, long-standing relationship with the Department of Veterans Affairs, providing critical oncology medications through blanket purchase agreements and Federal Supply Schedule contracts. Their work supports VA’s hematologic and solid tumor treatment protocols, ensuring reliable access to specialty drugs for veteran patients. The pattern of repeated awards over multiple years indicates a trusted vendor status, with the VA relying on Daiichi Sankyo for both new product introductions and sustained supply of established therapies. The primary NAICS code 325412 reflects core competency in pharmaceutical preparation manufacturing, specifically the formulation and production of oral solid dosage forms used in oncology and hematology. The company’s market positioning is that of a niche supplier of targeted cancer therapeutics, serving government healthcare systems requiring high-assurance, low-volume specialty drug production. Daiichi Sankyo, Inc. operates as a 2L entity headquartered in Basking Ridge, New Jersey, with no disclosed federal certifications. Its government market presence is centered on direct pharmaceutical supply to federal healthcare providers, particularly within the VA network, leveraging its manufacturing infrastructure to meet stringent regulatory and logistical demands of federal medical programs.